在本文中

• 利來

關注您最喜歡的股票

索帕圖像|

輕火箭|

蓋蒂圖片社

禮來公司

正在通過一個新網站震撼制藥行業，該網站提供遠程醫療處方和某些藥物的直接送貨上門服務，包括其炙手可熱的減肥藥物 Zepbound，以擴大患者的獲取范圍。

一些分析師表示，該公司周四宣布的直接面向消費者的舉措是大型制藥商的首次此類舉措，但不一定會單獨顛覆制藥行業和處方藥供應鏈。

但一些分析師表示，其他制藥商可能會效仿，推出自己的直接面向消費者的模式。

這可能會給許多批評者所說的美國復雜的藥品分銷、定價和處方系統帶來更大的壓力，他們認為這種結構導致了價格上漲和患者選擇減少。

BMO 資本市場分析師埃文·塞格曼 (Evan Seigerman) 告訴 CNBC：“顛覆的可能性總是存在。我認為永遠不應該排除任何形式的顛覆。”

“我認為明天不一定會發生這種情況，但我認為你永遠不應該認為事情不會改變。”

禮來公司推出新平臺之際，其他公司正采取某種方式擾亂藥品體系，部分原因是它們面臨著削減消費者成本和提高定價透明度的更大政治壓力。

這些行動是在立法者在新立法中針對藥品供應鏈中間商以及拜登政府采取自己的措施控制藥品價格之際采取的，例如六年來首次賦予醫療保險通過談判降低藥品價格的權力歷史。

禮來公司 (Eli Lilly) 表示，其名為 LillyDirect 的新舉措旨在增加慢性病藥物的獲取，包括廣受歡迎的減肥藥。

這些治療方法在過去一年中因幫助患者減掉多余的體重而需求猛增，但目前卻受到供應限制和對潛在有害仿冒品的擔憂的困擾。

塞格曼表示，患者還需要排很長的等候名單才能與肥胖醫學專家會面，以便為他們開出藥物，這是禮來公司希望解決的問題。

Eli Lilly's Zepbound won Food and Drug Administration approval just two months ago, but some analysts say it could garner more than $1 billion in sales in its first year on the market.

LillyDirect won't significantly disrupt the industry

Eli Lilly's site eliminates the need for a patient to visit the doctor's office to get a prescription and, in some cases, for a pharmacy to fill it.

But some analysts said Eli Lilly's site alone will not significantly threaten the traditional drug distribution system, which involves a multitiered network of manufacturers, drug wholesalers, pharmacies and pharmacy benefit managers, or PBMs.

"I don't think PBMs and the whole infrastructure that we have are going anywhere," Seigerman told CNBC. "I think what [Eli Lilly] really did was identify some friction points in getting these products[weight loss drugs] to patients, and they're coming up with a way to solve for that."

"From my understanding, it's just that there's no retail pharmacy where a patient is having to go hunt for that particular [drug] dose, it's being shipped right to them," he said of Eli Lilly's services.

Eli Lilly's site connects patients with an independent telehealth provider who can prescribe any FDA-approved weight loss drug or other medications for diabetes and migraines. If the prescribed treatment is Eli Lilly's, the patient can have a third-party online pharmacy deliver it to their door.

Patients will also receive Eli Lilly's discounts for drugs if they qualify for the company's savings-card programs, the company noted in a release. One program allows people with insurance coverage for Zepbound, which costs more than $1,000 per month, to pay as little as $25 out-of-pocket. Meanwhile, those whose insurance does not cover the drug may be able to pay as low as $550.

Some experts view that transparent pricing as a shot across the bow to PBMs, the largest of which are owned by CVS, UnitedHealth Group and Cigna.

Drugmakers have long complained that they give PBMs steep drug discounts in exchange for higher placement on a formulary — an insurance plan's list of preferred medications — only for those middlemen to not pass along savings to patients.

But Eli Lilly's savings-card program and new site won't cut PBMs out of the equation.

"If you still use your health insurance to get these drugs through [Eli Lilly's] website, it's still going to get processed by a PBM," Jeff Jonas, a Gabelli Funds portfolio manager, told CNBC.

Patients who get drugs such as Zepbound from Eli Lilly's site can choose to pay with cash to avoid PBMs altogether. But Bernstein analysts said in a Thursday note that they expect the "vast majority" of potential weight loss drug users to get medications through insurance.

Other drugmakers could follow Eli Lilly

更多制藥公司可以采用與禮來公司類似的方法。

Cantor Fitzgerald 分析師 Louise Chen 表示，制藥商可以從使用直接面向消費者的藥房模式銷售高銷量藥品中獲益最多。

陳在給 CNBC 的電子郵件中寫道：“考慮到你們的努力規模，這對于更大的藥物來說可能是有意義的。”

“你會得到更多的回報，并且會接觸到更多的人。”

但陳表示，對于制藥商來說，采用更小、更專業的藥物（例如治療復雜、慢性或罕見疾病的藥物）來追求直接面向消費者的模式可能會更加困難。

例如，某些藥物需要專門的給藥培訓，例如通過靜脈注射將治療藥物注射或輸注到患者的靜脈中。

在其他公司近幾個月采取簡化系統的行動后，確實采用直接面向消費者的方式的制藥商可能會給該國傳統藥品供應鏈帶來更大的壓力。

其中包括

，該公司于 12 月宣布計劃徹底改革其處方藥定價業務模式，采用類似于億萬富翁馬克·庫班 (Mark Cuban) 的直接面向消費者的藥房 Cost Plus Drugs 的模式。

醫療保健巨頭 Cigna 也在 11 月宣布，其 PBM 將提供與 Cuban 的合資企業類似的定價模式。

Cost Plus Drugs 旨在通過以高于成本 15% 的加價加上藥房費的方式銷售藥品，從而大幅降低藥品價格。

該公司已經震動了更廣泛的醫療保健行業：CVS 在今年夏天遭受了打擊，當時加州一家主要健康保險公司 Blue Shield of California 宣布將不再使用該公司作為其 PBM，而是將與其他幾家公司合作企業，包括庫班公司和亞馬遜藥房。

熱點：麗莎 公司 行業